AZTA Azenta, Inc.

BEARISH Impact: 8/10 8-K
Horizon immediate Filed May 5, 2026 Processed 15d 2h ago SEC 0001628280-26-030677
8-K Item 2.02: Earnings release
Latest settled — T+5d
AZTA ▼ -4.62% at T+5d
SHORT call ✓ call won +4.62% · α vs SPY +5.76% · entry $18.38 → $17.53
Next anchor: T+20d in 14d
Currently $18.57 · -1.03% from $18.38 entry (call sign-flipped)
Entry anchored
May 5, 2026
via day open
T+1d
+1.03%
call -1.03% · α -1.36%
$18.57
settled 14d ago
T+5d
-4.62%
call +4.62% · α +5.76%
$17.53
settled 8d ago
T+20d
call — · α —
in 14d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Azenta reported Q2 FY2026 revenue of $145M (+1% reported, -3% organic), non-GAAP EPS of ($0.04) vs $0.01 a year ago, and a $149M goodwill impairment. FY2026 guidance was sharply cut: organic revenue now expected -2% to +1% (prior 3-5% growth) and Adjusted EBITDA margin expected -125bps to flat (prior +300bps expansion). Long-range plan extended to 2029, and B Medical Systems sale remains uncertain. The filing signals worsening demand and execution issues.

Key Financial Metrics

Guidance
$603M-$621M
lowered
Free Cash Flow
$5.0M
Gross Margin
42.8%

Actionable Insight

Expect sharp downside pressure as guidance cuts confirm deteriorating demand and execution. Monitor the May 6 earnings call for details on cost actions and B Medical sale timeline. The lack of buyback execution despite authorization suggests management priorities elsewhere.

Key Facts

  • Q2 FY2026 revenue: $145M, up 1% YoY reported, organic down 3%
  • GAAP diluted EPS from continuing ops: ($3.41) vs ($0.43) YoY, including $149M goodwill impairment
  • Non-GAAP diluted EPS: ($0.04) vs $0.01 YoY
  • FY2026 organic revenue guidance lowered to -2% to +1% from prior 3-5% growth
  • FY2026 Adjusted EBITDA margin outlook cut to -125bps to flat from prior +300bps expansion
  • Long-range plan extended from 2028 to 2029
  • B Medical Systems sale delayed; buyer has not secured financing
  • No share repurchases executed under $250M program

Financial Impact

Goodwill impairment of $149M; guidance revision implies $30-40M revenue reduction vs prior outlook

revenueepsebitdagoodwill

Risk Factors

  • Further demand weakening in life sciences tools market
  • B Medical Systems sale falling through, requiring additional cash outflows or write-downs
  • Additional impairment charges if revenue trends continue declining
  • Dilution from potential equity offering if cash needs arise

Market Snapshot

Exchange
Nasdaq
Sector
Special Industry Machinery, NEC
Analyst Consensus
64% bullish (14 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-030677
Document: azta-20260505.htm0001628280-26-030677
Document: 0001628280-26-030677-index-headers.html0001628280-26-030677
Document: 0001628280-26-030677-index.html0001628280-26-030677
Document: 0001628280-26-030677.txt0001628280-26-030677
8-K Data (Synthetic)0001628280-26-030677
2 reports for AZTA
Performance horizon
Filters
Rows
Reports for AZTA — sortable, filterable
Type Now
May 5, 2026
15d ago
8-K
BEARISH ★ 8/10
$18.38 $17.53▲ +4.62%▲ +5.76%$18.57 (−1.03%)
Apr 7, 2026
6w ago
8-K
NEUTRAL ★ 6/10
$21.71 $24.26▲ +11.75%▲ +6.42%$18.57 (−14.46%)
Showing 2 of 2

US Market Status

Market Closed — Opens Thu (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access